WO2000045840A8 - Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence - Google Patents

Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence

Info

Publication number
WO2000045840A8
WO2000045840A8 PCT/US2000/002866 US0002866W WO0045840A8 WO 2000045840 A8 WO2000045840 A8 WO 2000045840A8 US 0002866 W US0002866 W US 0002866W WO 0045840 A8 WO0045840 A8 WO 0045840A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
treating
dna methylation
essential role
Prior art date
Application number
PCT/US2000/002866
Other languages
French (fr)
Other versions
WO2000045840A1 (en
Inventor
Michael J Mahan
Douglas M Heithoff
David A Low
Robert L Sinsheimer
Original Assignee
Univ California
Michael J Mahan
Douglas M Heithoff
David A Low
Robert L Sinsheimer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Michael J Mahan, Douglas M Heithoff, David A Low, Robert L Sinsheimer filed Critical Univ California
Priority to CA002359469A priority Critical patent/CA2359469A1/en
Priority to EP00910070A priority patent/EP1150711A1/en
Priority to BR0007966-9A priority patent/BR0007966A/en
Priority to AU32221/00A priority patent/AU776864B2/en
Priority to MXPA01007747A priority patent/MXPA01007747A/en
Priority to NZ512685A priority patent/NZ512685A/en
Priority to JP2000596959A priority patent/JP2002536339A/en
Publication of WO2000045840A1 publication Critical patent/WO2000045840A1/en
Publication of WO2000045840A8 publication Critical patent/WO2000045840A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed towards vaccine compositions containing pathogenic bacteria such as Salmonella having non-reverting genetic mutations which alter activity of DNA adenine methylase (Dam) and methods using these compositions to elicit an immune response. The invention also provides methods for preparing vaccines as well as screening methods to identify agents which may have anti-bacterial activity.
PCT/US2000/002866 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence WO2000045840A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002359469A CA2359469A1 (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
EP00910070A EP1150711A1 (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
BR0007966-9A BR0007966A (en) 1999-02-02 2000-02-02 Compositions and methods for the treatment and prevention of pathogenic bacterial infection based on the essential function of DNA methylation in bacterial virulence
AU32221/00A AU776864B2 (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence
MXPA01007747A MXPA01007747A (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence.
NZ512685A NZ512685A (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of DNA methylation in bacterial virulence
JP2000596959A JP2002536339A (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infections based on the essential role of DNA methylation in bacterial toxicity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US24195199A 1999-02-02 1999-02-02
US09/241,951 1999-02-02
US30560399A 1999-05-05 1999-05-05
US09/305,603 1999-05-05
US49561400A 2000-02-01 2000-02-01
US09/495,614 2000-02-01

Publications (2)

Publication Number Publication Date
WO2000045840A1 WO2000045840A1 (en) 2000-08-10
WO2000045840A8 true WO2000045840A8 (en) 2001-03-22

Family

ID=27399537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002866 WO2000045840A1 (en) 1999-02-02 2000-02-02 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence

Country Status (8)

Country Link
EP (1) EP1150711A1 (en)
JP (1) JP2002536339A (en)
AU (1) AU776864B2 (en)
BR (1) BR0007966A (en)
CA (1) CA2359469A1 (en)
MX (1) MXPA01007747A (en)
NZ (1) NZ512685A (en)
WO (1) WO2000045840A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6602680B2 (en) 2000-07-14 2003-08-05 The Regents Of The University Of California Production of gabaergic cells
GB0029379D0 (en) * 2000-12-01 2001-01-17 Arrow Therapeutics Ltd A method for identifying enzyme inhibitors
ITRM20010295A1 (en) * 2001-05-30 2002-12-02 Stresstech S R L METHOD FOR OBTAINING NON-VIRULENT PATHOGENIC MICRO-ORGANISMS THROUGH A MODIFICATION OF THE PHYSICAL AND / OR DYNAMIC STATE OF THEIR BI-MEMBRANES
JP2003189861A (en) * 2001-12-25 2003-07-08 Japan Science & Technology Corp Control of expression of bactericidal mobility related gene group
JP2022543668A (en) 2019-08-09 2022-10-13 ナットクラッカー セラピューティクス， インコーポレイテッド Microfluidic device and method of use
WO2021107013A1 (en) * 2019-11-29 2021-06-03 国立研究開発法人理化学研究所 Adjuvant composition

Also Published As

Publication number Publication date
EP1150711A1 (en) 2001-11-07
WO2000045840A1 (en) 2000-08-10
JP2002536339A (en) 2002-10-29
BR0007966A (en) 2001-11-06
AU3222100A (en) 2000-08-25
AU776864B2 (en) 2004-09-23
CA2359469A1 (en) 2000-08-10
MXPA01007747A (en) 2002-07-02
NZ512685A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ATE173166T1 (en) NEW BACTERIAL VACCINES USING VACCINE STRAINS OF PATHOGENIC BACTERIA
WO2002034773A3 (en) Streptococcal genes
PL344851A1 (en) Bacterium of salmonella type and vaccine containing that bacterium for protecting animals against salmonellosis and method of obtaining such vaccine
WO2000045840A8 (en) Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
WO2000061724A3 (en) Anti-bacterial vaccine compositions
SI0716852T1 (en) Pharmaceutical formulations of cefaclor
BR0012973B1 (en) Use of lactic acid bacteria belonging to the genus Bifidobacterium, and food or pharmaceutical composition.
WO2009008924A3 (en) Methods of preventing and treating viral infections by inhibiting the deisgylation activity of otu domain-containing viral proteins
TW200502384A (en) Live attenuated bacteria of the species actinobacillus pleuropneumoniae
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
EP1303300A4 (en) Compositions and methods for treatment of candidiasis
GB2331521A (en) Vaccine preparations
DE69739592D1 (en) DETECTION, PREVENTION AND TREATMENT OF PAPILLOMATOUS DIGITAL DERMATITIS
ZA200002615B (en) Live attenuated bacteria for use in a vaccine.
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
FR2809960B1 (en) ADJUVANT COMPOSITION OF THE IMMUNE RESPONSE COMPRISING FHA PROTEIN OR A FRAGMENT OF FHA PROTEIN IN FREE FORM, AND IMMUNOGENIC OR VACCINE COMPOSITION CONTAINING SUCH ADJUVANT COMPOSITION
WO2000077177A3 (en) Isolation of a human retrovirus
GB9726233D0 (en) Vaccines containing attenuated bacteria
Kashyap et al. Salmonella. typhi OMPs induced immunomodulation in peritoneal macrophages
WO2004003153A8 (en) Live replicating spumavirus vector
WO2001051649A3 (en) Identification of virulence determinants
ES2115550A1 (en) Anti-Pasteurella piscicida (DI) vaccine for the prevention of pasteurellosis disease in gilthead bream and sea-bass, and process for obtaining it
AP1679A (en) Outer surface proteins, their genes, and their use.
EP0178928A3 (en) Vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 32/2000 UNDER (30) REPLACE "NOT FURNISHED" BY "09/495614"

WWE Wipo information: entry into national phase

Ref document number: 2001/05305

Country of ref document: ZA

Ref document number: 200105305

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 512685

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2359469

Country of ref document: CA

Ref country code: CA

Ref document number: 2359469

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007747

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 596959

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 32221/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000910070

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000910070

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 32221/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000910070

Country of ref document: EP